Top Markets
Coin of the day
Lexeo Therapeutics, Inc. Common Stock Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. Common Stock

LXEO
Rangering i aksjer #15117
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical... Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Aksjekurs
$4.74
Sist synkronisert: 2026-08-31
Markedsverdi
$372.19M
Endring (1 dag)
-2.47%
Endring (1 år)
-1.04%
Land
US
Handel Lexeo Therapeutics, Inc. Common Stock (LXEO)

Kategori

Historikk for aksjesplitt for Lexeo Therapeutics, Inc. Common Stock (LXEO)
Aksjen Lexeo Therapeutics, Inc. Common Stock (symbol: LXEO) har gjennomgått totalt 0 aksjesplitt.
Den nyeste splittelsen skjedde Sep 01, 2026.
Én LXEO-aksje kjøpt før Sep 01, 2026 tilsvarer i dag 0 LXEO-aksjer.
Liste over aksjesplitt
År Splitt Multiplikator Kumulativ multiplikator
Ikke nok data for de angitte datoene.
Aksjesplitt for lignende selskaper eller konkurrenter
Selskap Antall aksjesplitt Kumulativ multiplikator Land
1 x2
US
0 -
NL
1 x3
AU
0 -
US
0 -
CH